Do I need to continue taking Almonertinib once I start taking it?

Almonertinib (Almonertinib) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), mainly used to treat patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). In clinical practice, the efficacy of ametinib relies on the continuous inhibition of the EGFR signaling pathway in tumor cells. Therefore, it is usually recommended that once patients start taking the drug, they should try to take it continuously and uninterrupted to ensure stable blood concentration and maintain continued suppression of tumor cells.

During treatment, if mild or tolerable side effects occur, doctors usually provide symptomatic treatment or temporarily adjust the dose rather than discontinuing the medication on their own. Unplanned interruptions or frequent missed doses may lead to a decrease in drug concentration in the body, allowing tumor cells to regain growth signals, thereby increasing the risk of disease progression or drug resistance. Therefore, in order to achieve the best therapeutic effect, patients should strictly follow the doctor's instructions and take medication on time, and keep records of daily medication.

However, in some special cases, such as severe adverse reactions (such as significant skin rash, abnormal liver function, or heart problems), your doctor may recommend temporarily discontinuing the drug or adjusting the dose. In this case, the patient must be under the guidance of professional medical staff and cannot decide to stop or resume medication on his own. Symptoms and biochemical indicators should be closely monitored during drug withdrawal, and treatment should be resumed after physician evaluation to minimize the risk of impaired efficacy and disease rebound.

In addition, long-term continuous medication needs to be accompanied by regular follow-up, including imaging examinations, tumor marker detection, blood routine, liver and kidney function assessment, etc., in order to understand the efficacy and safety in a timely manner. Once the treatment goal is achieved or the disease progresses, doctors will adjust the treatment plan according to the specific situation, including continued use, dose adjustment, or replacement of other targeted drugs. Therefore, the continuous administration of ametinib is not only an important prerequisite to ensure efficacy, but also a key measure to manage side effects and optimize treatment results.

Reference link:https://www.drugs.com